Related Experiment Video

Updated: Aug 28, 2025

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

18.4K

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75

Emi Takashita1, Seiya Yamayoshi2, Shuetsu Fukushi1

  • 1National Institute of Infectious Diseases, Tokyo, Japan.

The New England Journal of Medicine
|September 19, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.3K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.4K

Related Experiment Videos

Last Updated: Aug 28, 2025

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

18.4K
Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.3K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.4K

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

138
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
138
Subviral Agents01:29

Subviral Agents

84
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
84

Articles linked to this work by shared authors, journal, and citation graph.

Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes.

Protein science : a publication of the Protein Society·2026

An endonuclease inhibitor unlocks the PA-X shutoff mechanism in influenza A virus.

Cell reports·2026

Near real-time data on the human neutralizing antibody landscape to influenza virus as of early 2026 to inform vaccine-strain selection.

Virus evolution·2026

Sensitivity Enhancement by Dual Deflection Electrodes in an Electrospray Ionization Source.

Rapid communications in mass spectrometry : RCM·2026

A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.

Vaccine·2026

Cross-neutralization of SARS-CoV-2 BA.3.2.2 lineage by JN.1 mRNA vaccine-induced immunity.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Esophageal Cancer.

The New England journal of medicine·2026

Trial of a Maternal Diet Rich in Eggs and Peanuts to Reduce Infant Allergy.

The New England journal of medicine·2026

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.

The New England journal of medicine·2026

Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal.

The New England journal of medicine·2026

RNA virome comparison between sylvatic and urban-interface mosquitoes from Southeastern Brazil.

Frontiers in cellular and infection microbiology·2026

Mpox in the Republic of Korea from 2022 to June 2026: Epidemiological Trends and the First Clade Ib Case.

Public health weekly report·2026

Cardiac MRI-guided therapeutics in ischemic cardiomyopathy: impact on heart-team consensus and outcomes.

Frontiers in cardiovascular medicine·2026

Re-evaluating variability of circulating miR-122 in healthy volunteers: Implications for biomarker qualification in drug-induced liver injury.

British journal of clinical pharmacology·2026

Divergent host adaptation in Marburg virus: a hypothesis-generating framework for prioritizing non-traditional reservoirs.

BMC genomics·2026

MicroRNA-122 as a regulator and biomarker of liver disease.

Journal of molecular medicine (Berlin, Germany)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us